Patients with de novo lesions in small-vessel disease (SVD) may have a higher risk of major adverse cardiovascular events (MACE) when they are treated with the current-generation drug-eluting stents (DES) compared with the new-generation paclitaxel drug-coated balloons (DCB), new data suggest.